US biotech, Altavant Sciences, has expanded its pipeline with the addition of a potentially life-saving treatment for post-lung transplant patients following the acquisition of private Swiss drug development company Onspira Therapeutics.
OSP-101 is a novel inhaled interleukin-1 receptor antagonist (IL-1Ra) with orphan drug designation from the FDA. It is currently in preclinical development for the treatment of bronchiolitis obliterans syndrome (BOS), the leading non-infectious complication following lung transplantation and a major cause of death in these patients.
“Adding OSP-101 to our pipeline creates significant value for Altavant, while also furthering our mission to develop drugs for patients with very serious and rare lung diseases,” said William T. Symonds, CEO of Altavant.
“Although a majority of lung transplant recipients develop this life-threatening condition, there are no treatments approved specifically for BOS and the current therapies have limited efficacy.”